

ORDERING INFORMATION

PRODUCT	APPLICATION	SIZE	STORAGE	SHELF-LIFE	REFERENCE
PlaBiTe Growth® L	Research use only	100 mL	-80°C to -20°C	24 months	PBT-GL-RUO-100
PlaBiTe Growth® L	Research use only	500 mL	-80°C to -20°C	24 months	PBT-GL-RUO-500

Plasma-Free Human Platelet Lysate for Advanced Cell Culture

Xeno-Free | Plasma-Free | Research Use Only (RUO)

PlaBiTe Growth® L is a plasma-free human platelet lysate developed to provide a consistent source of growth factors and bioactive proteins for advanced cell culture and biomedical research applications. Designed for laboratories seeking to reduce dependence on animal-derived supplements, PlaBiTe Growth® L provides a human-derived alternative for more defined and xeno-free culture conditions.

The plasma-free formulation of PlaBiTe Growth® L is designed to minimize the presence of plasma-derived components, including fibrinogen, immunoglobulins, complement proteins, coagulation factors and carrier proteins. This approach is intended to simplify cell culture workflows by avoiding routine heparin supplementation while reducing the variability associated with plasma-derived constituents.

PlaBiTe Growth® L is manufactured to produce a standardized product with minimal batch-to-batch variation, by pooling platelet lysates from multiple donors.

SOURCE & QUALITY CONTROL

PlaBiTe Growth® L is obtained from human blood donations collected at European blood bank certified centers. Each donor unit has been tested for infectious diseases including Hepatitis B Virus (HBV), Hepatitis C Virus

(HCV), Human Immunodeficiency Virus (HIV-1/2) and Syphilis.

Each manufacturing batch undergoes quality control testing including sterility, endotoxin, mycoplasma and pH.

Lot Acceptance Criteria:

- Sterility Testing: Pass
- pH: 7-7.5
- Endotoxin: <1 EU/mL
- Mycoplasma: Not detected

Certificate of Analysis (CoA) is available on request.

INTENDED USE

PlaBiTe Growth® L is for research use only (RUO) and not intended for human or animal diagnostic or therapeutic use. For safety precautions, please see the appropriate Safety Data Sheet (SDS).

APPLICATIONS

- **Cell Therapy Process Development**
Evaluate human-derived supplements during process optimization.
- **Serum-Free Media Development**
Reduce reliance on animal-derived supplements.
- **Regenerative Medicine Research**
For non-clinical investigations requiring human platelet-derived growth factors.

PREPARATION OF CELL CULTURE MEDIUM

1. Preferably, thaw PlaBiTe Growth® L overnight at 4°C. Alternatively, thaw at room temperature immediately before use.
2. Prepare complete cell culture medium by adding PlaBiTe Growth® L to basal medium (e.g. MEM α , DMEM). Preparation of complete cell culture medium should be performed following the general guidelines for specific cell types.

PlaBiTe Growth® L does not require the addition of heparin.

Please note: Final concentration of PlaBiTe Growth® L in cell culture medium can vary depending on cell type and experimental conditions. It is recommended to determine the optimal concentration – typically between 1% and 10% (v/v)– for the cells of interest.

3. Complete cell culture medium can be stored at 4°C and is stable for up to 14 days.

STORAGE AND STABILITY

PlaBiTe Growth® L is stable until the expiration date stated on the label. PlaBiTe Growth® L is

most stable when stored frozen at -80°C to -20°C until use.

Upon first thawing, aliquoting into single-use volumes is recommended. Repeated freeze-thaw cycles should be avoided.

Once thawed, PlaBiTe Growth® L can be stored at 4°C up to 14 days.

STERILITY

PlaBiTe Growth® L is aseptically processed.

SAFETY INFORMATION

Follow the handling instructions outlined in the Safety Data Sheet (SDS). Wear appropriate protective eyewear, clothing and gloves.

PlaBiTe Growth® L is manufactured from platelets obtained from human blood donations following European and local guidelines.

Note: Although donor units undergo extensive screening, proper safety precautions for potentially infectious agents must be taken. All human blood products should be handled in accordance with currently acceptable biosafety practices and guidelines for the prevention of blood borne viral infections (BSL-2).